ライフサイエンスコーパス: tartrate

1 lution of YiaK alone and in complex with NAD-tartrate.

2 anic host selectivity to preferentially bind tartrate.

3 ic charges and can be mimicked by suramin or tartrate.

4 ith higher specificity and potency than L(+)-tartrate.

5 presence of the competitive inhibitor, meso-tartrate.

6 d in AMTPS formed by Triton X-114 and sodium tartrate.

7 rats trained to discriminate saline from LSD tartrate (0.08 mg/kg).

8 rats trained to discriminate saline from LSD tartrate (0.08 mg/kg).

9 hosphonate (2.1 A), and a buffer additive, l-tartrate (1.7 A).

10 human donors received control or brimonidine tartrate (45 nM) for 1, 3, or 7 days.

11 two steps from dimethyl 2,3-O-benzylidene-d-tartrate (7).

12 attempted with a moderate dose of metoprolol tartrate, a beta-1-blocker that results in lesser clinic

13 s, we investigated the effect of varenicline tartrate, a relatively specific alpha4beta2 partial agon

14 s endogenously to the proximal region of the tartrate acid phosphatase (TRAP) gene promoter and suppr

15 We assessed the number of osteoclasts by tartrate-acid resistant acid phosphatase (TRAP)-positivi

16 meso-Tartrate also binds with a large DeltaC(p) value and lik

17 Although the binding of meso-tartrate also requires enzyme-bound K(+) and Mn(2+), the

18 Given the actions of varenicline tartrate and bupropion hydrochloride sustained-release (

19 changes in phenylalanine, dehydroascorbate, tartrate and formate were consistent with a higher deman

20 structures of active LasA as a complex with tartrate and in the uncomplexed form.

21 ducts of Cr(VI) reduction in the presence of tartrate and malate.

22 Metoprolol tartrate and MS produce similar hemodynamic and clinical

23 e-bound K(+) and Mn(2+), the binding of meso-tartrate and NAD is random.

24 Enzyme kinetics studies confirm that tartrate and the related D-malate are inhibitors of YiaK

25 omplexes with chiral ((R)/(S)-BINOL, diethyl tartrate) and achiral (piperazine and trigol) linkers wi

26 H,3H)-quinazoli nedione tartrate (ketanserin tartrate), and the non-selective 5-HT receptor agents, 2

27 rsenite, sodium arsenate, antimony potassium tartrate, and cadmium chloride.

28 (N-hydroxysuccinimide ester), disuccinimidyl tartrate, and dithiobis(succinimidyl) propionate, develo

29 ne-tartrate, d-dimethyl-2,3-O-isopropylidene-tartrate, and meso-erythritol, respectively.

30 caris suum will utilize L-aspartate, (2S,3R)-tartrate, and meso-tartrate as substrates with V/K value

31 dose of 25 mg carvedilol, 100 mg metoprolol tartrate, and placebo).

32 a C2-symmetric starting material, diethyl D-tartrate, and took advantage of a relay of diastereosele

33 Corey stien reagent, the Roush allylboronate tartrates, and the secondary amine Diels-Alder catalysts

34 s where ascorbic acid and antimony potassium tartrate are added and serve as reducing agents.

35 In this study, we have identified ammonium tartrate as a MS-compatible salt for HIC with comparable

36 ternary complex of the enzyme with NADP+ and tartrate as an inhibitor.

37 use of ascorbic acid and antimony potassium tartrate as reducing agents (as used in the colorimetric

38 lize L-aspartate, (2S,3R)-tartrate, and meso-tartrate as substrates with V/K values 10(-4)-10(-5) wit

39 ared carvedilol with short-acting metoprolol tartrate at different dose equivalents.

40 ), suggesting that K(+) is required for meso-tartrate binding.

41 dideoxyguanosine-5'-triphosphate, MnCl2, and tartrate, but their quaternary structure did not conform

42 dized by addition of dioxygen and a titanium tartrate catalyst to give epoxy alcohols with excellent

43 Our measurements indicate that tartrate, citrate, chloride, and nitrate anions are amon

44 ic method based on formation of the vanadate-tartrate complex.

45 Differences in Cu(2)(+)-tartrate complexes particle size and concentration were

46 apraclonidine hydrochloride, and brimonidine tartrate constitute the three topical alpha agonists tha

47 Ever since Pasteur noticed that tartrate crystals exist in two non-superimposable forms

48 Here, we show that cyclopamine tartrate (CycT) strongly suppresses the growth of subcut

49 hesized from l-dimethyl-2,3-O-isopropylidene-tartrate, d-dimethyl-2,3-O-isopropylidene-tartrate, and

50 on at least three different substrates (L(+)-tartrate, D-malate, and 3-isopropylmalate).

51 exposed to nicotine (6 mg kg(-1) of nicotine tartrate daily) or saline with an osmotic mini-pump impl

52 -1)) are consistent with assignment of the d-tartrate dehydratase (TarD) function.

53 late racemase, l-fuconate dehydratase, and d-tartrate dehydratase, the active site of TalrD/GalrD con

54 tes and inhibitors to different complexes of tartrate dehydrogenase (TDH) from Pseudomonas putida was

55 Tartrate dehydrogenase catalyzes the divalent metal ion-

56 drogenase, homoisocitrate dehydrogenase, and tartrate dehydrogenase, which have an (R)-hydroxyacid su

57 ration of the genome from the E protein in a tartrate density gradient.

58 In this study, a commercially available tartrate derivative was elaborated through a key late-st

59 allylboronates bearing the readily available tartrate derivative were obtained via sigmatropic rearra

60 Conversion of the adduct to a mixture of tartrate-derived ketals followed by separation of the di

61 10-15-membered rings was achieved by using a tartrate-derived linker to attach ene and yne subunits.

62 MeOH/H(2)O, revealed that the antimony(III)-tartrate dianion associates to solvent reaction products

63 In contrast, meso-tartrate does bind to E/K(+)/Mn(2+) but gives no signifi

64 e administered nicotine bitartrate or sodium tartrate either during adolescence (p29-43) or adulthood

65 r was not significantly enhanced by ammonium tartrate (Emax approximately 13%).

66 as well as thioether 8 were synthesized from tartrates employing Ley's "BDA" and "Dispoke" methodolog

67 s for the allylboration reaction between the tartrate ester and tartramide modified allylboronates an

68 ealed that the predominant species in Ti/PEG tartrate ester mixtures is a distinct 2:1 Ti-ligand comp

69 ic reaction of N-acetyl-d-alaninal 1 and the tartrate ester modified (E)-crotylboronate (R,R)-2.

70 s into the recently disputed report that PEG tartrate esters can reverse the enantioselectivity of th

71 e investigated by administering (-)-nicotine tartrate for 5 days either continuously in doses of 5.01

72 In the phase 3 Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease

73 gential flow filtration (TFF-DB) or glycerol tartrate gradient sedimentation (GT-DB) constitute 92% o

74 articles sedimented abnormally in a glycerol-tartrate gradient, indicating that the structure of the

75 more, GABA increased the potency of ammonium tartrate in enhancing [3H]flunitrazepam binding by 63%.

76 ctrometry (ESI-MS) analysis of antimony(III)-tartrate in frequently used solvent systems, ACN/H(2)O a

77 he superiority of carvedilol over metoprolol tartrate in one clinical trial is demonstrated, and mult

78 nalysis unexpectedly revealed the binding of tartrate in the active site.

79 that the selectivity obtained with ammonium tartrate in the HIC mobile phases is orthogonal to that

80 An abiotic formation of meso- and DL-tartrates in 80% yield via the cyanide-catalyzed dimeriz

81 de, sodium arsenite, and potassium antimonyl tartrate (in order of effectiveness), the same inducers

82 and crystal structures of 11 alkaline earth tartrates, including an unusual I(3)O(0) framework, [Ba(

83 tase binary complex erroneously positioned D-tartrate into the active site.

84 n an achiral gold surface in the presence of tartrate ion in the deposition solution, the chirality o

85 of 46 acid sugars and discovered that only d-tartrate is dehydrated, yielding oxaloacetate as product

86 e Mitsunobu reaction in which catalytic zinc tartrate is used to enhance the nucleophilicity of the t

87 perdinyl]ethyl]-2,4(1H,3H)-quinazoli nedione tartrate (ketanserin tartrate), and the non-selective 5-

88 By preparing a range of tartrate ligands with varying PEG chains lengths, the re

89 a-hydroxyl or carbonyl carboxylates, such as tartrate, malate, lactate, pyruvate, and mandelate, sign

90 nicotine replacement therapy and varenicline tartrate may aid cessation treatment.

91 ues of about 6.3 and 8.3, while that for V/K(tartrate) (measured from pH 7.5 to pH 9) exhibits a pK(a

92 A tartrate-mediated nucleophilic epoxidation involving hyd

93 imilarity to a product of ttuD essential for tartrate metabolism in Agrobacterium vitis.

94 n, we monitor the crystallization of lithium tartrate MOFs, observing the successive crystallization

95 Metoprolol tartrate (MPT) concentration (10 and 40% in Eudragit RSP

96 n = 498) or 50- to 200-mg dose of metoprolol tartrate (n = 737), each twice daily.

97 Meso-tartrate occupies a position close to that of the bound

98 y subjects was treated with 0.2% brimonidine tartrate ophthalmic solution to induce pupil size reduct

99 the acid phosphatase inhibitors citrate and tartrate or the protein serine/threonine phosphatase inh

100 The ligands Mn(2+), meso-tartrate, oxalate, and reduced nicotinamide adenine dinu

101 emotherapy with trivalent potassium antimony tartrate (PAT) and, more importantly, pentavalent antimo

102 t to killing by the drug potassium antimonyl tartrate (PAT).

103 n was induced in the presence of citrate and tartrate, perhaps by the activity of a divergent histidi

104 Calcium forms unique l-, meso-, and d,l-tartrate phases which persist to 220 degrees C.

105 e small orally, available molecule, Posiphen tartrate (Posiphen), lowers secreted (s) amyloid-beta pr

106 gamma-aminobutyric acid A receptor, zolpidem tartrate presents a potential treatment mechanism for ot

107 y, coupled with the remarkable efficiency of tartrate production from glyoxylate, merits consideratio

108 ous crystallographic studies compiled on the tartrate-rat prostatic acid phosphatase binary complex e

109 sually separated into tartrate-resistant and tartrate-refractory, which is reported as the prostatic

110 sphatase-positive osteoblasts and diminished tartrate resistance acid phosphatase-positive osteoclast

111 itonin receptor (Calcr), acid phosphatase 5, tartrate resistant (Acp5), cathepsin K (Ctsk), and TNF s

112 Meanwhile, CLA significantly reduced femur tartrate resistant acid phosphatase (TRAP) activity, sug

113 Hemin inhibits transcription of the tartrate resistant acid phosphatase (TRAP) gene.

114 en c-src proto-oncogene from the promoter of tartrate resistant acid phosphatase (TRAP), a gene that

115 stal side of the molars until 6 months using tartrate resistant acid phosphatase (TRAP).

116 The enzyme tartrate resistant acid phosphatase (TRAP, two isoforms

117 nduce osteoclast formation was determined by tartrate resistant acid phosphatase assay.

118 of nuclear factor-kappaB ligand (RANKL) and tartrate resistant acid phosphatase were significantly d

119 iding cells expressing the osteoclast marker tartrate resistant acid phosphatase, in vivo.

120 sections were assessed for the abundance of Tartrate Resistant Acid Phosphatase-positive osteoclasts

121 A parallel series of tartrate resistant acid phosphatase-stained sections wer

122 The isolated approximately 28-kDa enzyme was tartrate resistant and displayed narrow substrate specif

123 id phosphatase activity that, unlike Map, is tartrate resistant.

124 urface membrane phospho-monoesterase, i.e. a tartrate-resistant acid phosphatase (Cl MAcP) was also f

125 However, the absence of tartrate-resistant acid phosphatase (TRAP) activity and

126 ic differentiation as evidenced by increased tartrate-resistant acid phosphatase (TRAP) activity and

127 the number of multinuclear cells expressing tartrate-resistant acid phosphatase (TRAP) activity prod

128 The inhibition of osteoclastogenesis and tartrate-resistant acid phosphatase (TRAP) activity was

129 ounterparts they are larger, fail to express tartrate-resistant acid phosphatase (TRAP) activity, and

130 e colocalization of messenger RNA (mRNA) for tartrate-resistant acid phosphatase (TRAP) and cathepsin

131 toplasmic, calcineurin-dependent 1 (NFATc1), tartrate-resistant acid phosphatase (TRAP) and cathepsin

132 one healing/BH), number of cells stained for tartrate-resistant acid phosphatase (TRAP) and immunohis

133 ere performed on media and cell lysates, and tartrate-resistant acid phosphatase (TRAP) and mRNA dete

134 Serial sections were reacted for tartrate-resistant acid phosphatase (TRAP) and nonspecif

135 -dihydroxycholecalciferol and coincided with tartrate-resistant acid phosphatase (TRAP) expression, a

136 d alkaline phosphatase (AP) for osteoblasts; tartrate-resistant acid phosphatase (TRAP) for osteoclas

137 ast differentiation, plays a pivotal role in tartrate-resistant acid phosphatase (TRAP) gene expressi

138 a novel CD gene regulated by the osteoclast tartrate-resistant acid phosphatase (TRAP) gene promoter

139 e sialoprotein (BSP), osteocalcin (OCN), and tartrate-resistant acid phosphatase (TRAP) immunohistoch

140 IL-4 down-regulates expression of tartrate-resistant acid phosphatase (TRAP) in mature ost

141 ecessary for activation of target genes like tartrate-resistant acid phosphatase (TRAP) in osteoclast

142 The tartrate-resistant acid phosphatase (TRAP) is present in

143 d hematoxylin and eosin and subjected to the tartrate-resistant acid phosphatase (TRAP) method.

144 These MNCs were also positive for tartrate-resistant acid phosphatase (TRAP) mRNA and TRAP

145 Tartrate-resistant acid phosphatase (TRAP) plays an impo

146 le extracts of PRF membranes as indicated by tartrate-resistant acid phosphatase (TRAP) staining and

147 Tartrate-resistant acid phosphatase (TRAP) staining show

148 was analyzed by immunohistochemistry, using tartrate-resistant acid phosphatase (TRAP) staining to i

149 Tartrate-resistant acid phosphatase (TRAP) staining, res

150 uCT and osteoclast number was determined by tartrate-resistant acid phosphatase (TRAP) staining.

151 nalysis and immunohistochemical detection of tartrate-resistant acid phosphatase (TRAP) were also per

152 B ligand (RANKL), osteoprotegerin (OPG), and tartrate-resistant acid phosphatase (TRAP) were assessed

153 Histological sections stained for tartrate-resistant acid phosphatase (TRAP) were quantifi

154 a strongly reduced formation of multinuclear tartrate-resistant acid phosphatase (TRAP)(+) osteoclast

155 appaB ligand (RANKL), osteoprotegerin (OPG), tartrate-resistant acid phosphatase (TRAP), and activate

156 eptor activator of NK-kappaB ligand (RANKL), tartrate-resistant acid phosphatase (TRAP), and osteocla

157 on of matrix metallopeptidase 13 (MMP13) and tartrate-resistant acid phosphatase (TRAP), leading to a

158 Cells were fixed and stained for tartrate-resistant acid phosphatase (TRAP), Oregon Green

159 BL, TBA, the positive cells for tartrate-resistant acid phosphatase (TRAP), receptor act

160 significant elevation of the active form of tartrate-resistant acid phosphatase (TRAP)-5b.

161 sence of IL-4, we detected the appearance of tartrate-resistant acid phosphatase (TRAP)-negative mult

162 NF-kappaB ligand formation of multinucleated tartrate-resistant acid phosphatase (TRAP)-positive cell

163 st/periodontal ligament cells displayed more tartrate-resistant acid phosphatase (TRAP)-positive cell

164 counted as bone-associated multi-nucleated, tartrate-resistant acid phosphatase (TRAP)-positive cell

165 nificantly lower level of bone loss and less tartrate-resistant acid phosphatase (TRAP)-positive cell

166 igature-induced bone loss in mice with fewer tartrate-resistant acid phosphatase (TRAP)-positive cell

167 confirmed the decreased bone mass, increased tartrate-resistant acid phosphatase (TRAP)-positive cell

168 Tartrate-resistant acid phosphatase (TRAP)-positive oste

169 matoxylin and eosin, immunohistochemical, or tartrate-resistant acid phosphatase (TRAP)-stained secti

170 ltinucleated cells that stained positive for tartrate-resistant acid phosphatase (TRAP).

171 B ligand (RANKL), osteoprotegerin (OPG), and tartrate-resistant acid phosphatase (TRAP).

172 s showed increased numbers of multinucleated tartrate-resistant acid phosphatase (TRAP)/cathepsin K(+

173 otegerin expression, and a decrease in serum tartrate-resistant acid phosphatase (TRAP5b) concentrati

174 Tartrate-resistant acid phosphatase (type V) (TRAP) was

175 -cells, c1 (NFATc1), cathepsin K (Cstk), and tartrate-resistant acid phosphatase 5 (TRAP) with recept

176 unting of the in vivo bone resorption marker tartrate-resistant acid phosphatase 5b (TRACP 5b).

177 serum bone alkaline phosphatase (B-ALP) and tartrate-resistant acid phosphatase 5b (TRAP-5b), and ca

178 this was accompanied by an increase in serum Tartrate-resistant acid phosphatase 5b (TRAP5b) levels.

179 Even though tartrate-resistant acid phosphatase 5b was expressed, pr

180 rocollagen type-1 N-terminal propeptide, and tartrate-resistant acid phosphatase 5b were associated w

181 elopeptide of type I collagen) and TRACP-5b (tartrate-resistant acid phosphatase 5b).

182 procollagen type-1 N-terminal propeptide, or tartrate-resistant acid phosphatase 5b; these values cor

183 protein 2/4 [BMP2/4], osteocalcin [OCN], and tartrate-resistant acid phosphatase [TRAP]) analyses wer

184 ophospholipase A, and tartrate-sensitive and tartrate-resistant acid phosphatase activities and influ

185 d by analyses for calcium release or uptake, tartrate-resistant acid phosphatase activity (marker for

186 eveal a previously unrecognized link between tartrate-resistant acid phosphatase activity and interfe

187 nto osteoclasts was assessed by staining for tartrate-resistant acid phosphatase activity.

188 factor I concentrations and increased serum tartrate-resistant acid phosphatase and 25-hydroxyvitami

189 ive induction of OCL-specific genes, such as tartrate-resistant acid phosphatase and immunoreceptor O

190 Tartrate-resistant acid phosphatase and osteocalcin were

191 e, multinucleated osteoclasts that expressed tartrate-resistant acid phosphatase and were capable of

192 sed by enzyme-linked immunosorbent assay and tartrate-resistant acid phosphatase assay.

193 enerated with a transgenic construct using a tartrate-resistant acid phosphatase exon 1C promoter to

194 could collaborate with MITF to activate the tartrate-resistant acid phosphatase gene promoter depend

195 lammation were assessed by histomorphometry, tartrate-resistant acid phosphatase histoenzymology, and

196 e response was assessed by histomorphometry, tartrate-resistant acid phosphatase histoenzymology, bet

197 eptor type 4, nuclear factor kappa beta, and tartrate-resistant acid phosphatase immunostaining.

198 ollagen type 1 amino-terminal propeptide and tartrate-resistant acid phosphatase in KO mice confirmed

199 Osteoclast morphology was analyzed in tartrate-resistant acid phosphatase or F-actin-stained s

200 proximately 5% of the mononuclear cells were tartrate-resistant acid phosphatase positive, and these

201 specimens contained MNCs that were intensely tartrate-resistant acid phosphatase positive; approximat

202 We used the tartrate-resistant acid phosphatase promoter to target t

203 Tartrate-resistant acid phosphatase reaction and immunoh

204 were evaluated by hematoxylin and eosin and tartrate-resistant acid phosphatase staining (TRAP).

205 and function were assessed via quantitative tartrate-resistant acid phosphatase staining and degrada

206 Tartrate-resistant acid phosphatase staining demonstrate

207 Mmp-2, and Mmp-14 were expressed widely, and tartrate-resistant acid phosphatase staining notably was

208 ysis, microcomputed tomography analysis, and tartrate-resistant acid phosphatase staining revealed re

209 Tartrate-resistant acid phosphatase staining showed that

210 Tartrate-resistant acid phosphatase staining was used to

211 leated giant cells with varying intensity of tartrate-resistant acid phosphatase staining were regula

212 H&E and tartrate-resistant acid phosphatase staining were used t

213 human preosteoclastic cells was assessed by tartrate-resistant acid phosphatase staining, whereas th

214 al fluid (SF) macrophages were determined by tartrate-resistant acid phosphatase staining.

215 hemistry, and osteoclasts were enumerated by tartrate-resistant acid phosphatase staining.

216 ated osteoclastic cells was determined after tartrate-resistant acid phosphatase staining.

217 PBMC differentiation to OCs was confirmed by tartrate-resistant acid phosphatase staining; bone resor

218 mouse tails, using hematoxylin and eosin and tartrate-resistant acid phosphatase to confirm the prese

219 1, NF-kappaB ligand, cathepsin K, and serum tartrate-resistant acid phosphatase type 5b, but ankle l

220 received Scl-AbI, although levels of type 5b tartrate-resistant acid phosphatase were significantly l

221 TRAP (tartrate-resistant acid phosphatase)-positive osteoclast

222 xpress the purple, band 5 isozyme (Acp 5) of tartrate-resistant acid phosphatase, a binuclear metallo

223 ing matrix metalloproteinase 9, cathepsin K, tartrate-resistant acid phosphatase, and carbonic anhydr

224 ure, downregulation of the HCL markers CD25, tartrate-resistant acid phosphatase, and cyclin D1, smoo

225 assessed were bone resorption, detection of tartrate-resistant acid phosphatase, and determination o

226 m the center of the lesion, were stained for tartrate-resistant acid phosphatase, and histomorphometr

227 expression of the receptor for AGEs (RAGE), tartrate-resistant acid phosphatase, and proliferating c

228 ls, expression of receptors for AGEs (RAGE), tartrate-resistant acid phosphatase, and proliferating c

229 line phosphatase, bone alkaline phosphatase, tartrate-resistant acid phosphatase, and urinary cross-l

230 ophathalmia-associated transcription factor, tartrate-resistant acid phosphatase, cathepsin K, and be

231 gulate calcitonin receptor, but they express tartrate-resistant acid phosphatase, cathepsin K, and be

232 Sequencing of ACP5, encoding tartrate-resistant acid phosphatase, identified bialleli

233 crophage marker CD11b, the osteoclast marker tartrate-resistant acid phosphatase, or carbonic anhydra

234 Serum levels of human OPG-Fc and tartrate-resistant acid phosphatase-5b (TRAP-5b) were me

235 ssenger RNA and protein, along with elevated tartrate-resistant acid phosphatase-positive (TRAP+) OCs

236 ha tumors associated with significantly more tartrate-resistant acid phosphatase-positive (TRAP+) ost

237 ns, serum interleukin (IL)-1beta levels, and tartrate-resistant acid phosphatase-positive (TRAP+) ost

238 y features of the osteoclast: multinucleated tartrate-resistant acid phosphatase-positive cell format

239 lasts as the number of pits produced by each tartrate-resistant acid phosphatase-positive cell is red

240 Mice with depletion of PDGF-BB in the tartrate-resistant acid phosphatase-positive cell lineag

241 The number of multinucleated tartrate-resistant acid phosphatase-positive cells along

242 wer maturation into osteoclasts with reduced tartrate-resistant acid phosphatase-positive cells and d

243 These multinucleated, tartrate-resistant acid phosphatase-positive cells were

244 ion and maintenance of large multinucleated, tartrate-resistant acid phosphatase-positive cells.

245 quantified by histological identification of tartrate-resistant acid phosphatase-positive cells.

246 No tartrate-resistant acid phosphatase-positive multinuclea

247 ion were evaluated by counting the number of tartrate-resistant acid phosphatase-positive multinuclea

248 x metalloproteinase 9, and the generation of tartrate-resistant acid phosphatase-positive multinuclea

249 cent to and distal from pannus invasion, and tartrate-resistant acid phosphatase-positive multinuclea

250 (C453S) significantly enhanced the number of tartrate-resistant acid phosphatase-positive multinuclea

251 GM1 with primary bone marrow cells generated tartrate-resistant acid phosphatase-positive multinuclea

252 teoclast cell fusion, forming multinucleated tartrate-resistant acid phosphatase-positive osteoclast-

253 ysis was characterized by reduced numbers of tartrate-resistant acid phosphatase-positive osteoclasts

254 Catabolic activity was analyzed with tartrate-resistant acid phosphatase-positive osteoclasts

255 ells in vitro, as evidenced by a decrease in tartrate-resistant acid phosphatase-positive osteoclasts

256 yelomonocytic precursors into multinucleated tartrate-resistant acid phosphatase-positive osteoclasts

257 The number of tartrate-resistant acid phosphatase-positive osteoclasts

258 or induction of bone marrow macrophages into tartrate-resistant acid phosphatase-positive preosteocla

259 -29b, or -29c diminished formation of TRAP (tartrate-resistant acid phosphatase-positive) multinucle

260 Osteoclasts were counted in tartrate-resistant acid phosphatase-stained sections.

261 ained slides and osteoclasts were counted on tartrate-resistant acid phosphatase-stained slides.

262 rome), histomorphometry and immunohistology (Tartrate-Resistant Acid Phosphatase-TRAP, Osteocalcin an

263 ors including NFAT2, TRAF6, cathepsin K, and tartrate-resistant acid phosphatase.

264 lcin, bone-specific alkaline phosphatase, or tartrate-resistant acid phosphatase.

265 ) were stained with hematoxylin and eosin or tartrate-resistant acid phosphatase.

266 sections stained with hematoxylin-eosin and tartrate-resistant acid phosphatase.

267 orrelated with expression of the target gene tartrate-resistant acid phosphatase.

268 ent decrease in secretion of cathepsin B and tartrate-resistant acid phosphatase.

269 The number of osteoclasts was determined by tartrate-resistant acid phosphatase.

270 xacin; V-ATPase, vacuolar H(+)-ATPase; TRAP, tartrate-resistant acid phosphatase; alphaMEM D10, minim

271 eated with aPDT exhibited reduced numbers of tartrate-resistant acid-phosphatase-positive cells and m

272 Also, in both models, tartrate-resistant acidic phosphatase staining showed si

273 es based on the number of multinucleated and tartrate-resistant alkaline phosphatase-positive cells a

274 in the blood serum is usually separated into tartrate-resistant and tartrate-refractory, which is rep

275 vely expresses a unique externally oriented, tartrate-resistant, acid phosphatase on its surface memb

276 ssect the functional domains of this unique, tartrate-resistant, surface membrane enzyme.

277 l)-tropane-2beta-carboxylic acid methylester tartrate (RTI-55) whole-cell binding is increased by NEC

278 2-ylmethyl)-2-hydroxy-6-methoxybenzamide (+)-tartrate salt (raclopride; 0, 0.2, or 0.4 mg/kg) on the

279 ations involve resolution-crystallization of tartrate salt 6 followed by a one-pot procedure for the

280 that Map, like its eukaryotic homologs, is a tartrate-sensitive acid phosphatase.

281 A, phospholipase C, lysophospholipase A, and tartrate-sensitive and tartrate-resistant acid phosphata

282 ells were defined by increased expression of tartrate-sensitive prostatic acid phosphatase as a broad

283 itol) and its enantiomer (derived from l-(+)-tartrate) serve as key starting materials, which are ela

284 ed wine, they had been cross-validated in Zn-tartrate solutions.

285 In clone 33 LNCaP cells, L-(+)-tartrate suppresses the cellular PAcP activity and cause

286 ce daily) and 1518 to metoprolol (metoprolol tartrate, target dose 50 mg twice daily).

287 introduced ligands are malonate, succinate, tartrate, tartronate, pyruvate, and glyoxalate.

288 is an order of magnitude more selective for tartrate than malate.

289 periments of Rochelle salt (sodium potassium tartrate), the protein lysozyme, and has been employed f

290 e has higher selectivity for citrate over DL-tartrate, the formation of the aptamer:receptor complex

291 more closed conformation, the binding of NAD-tartrate to YiaK produces a more open active site.

292 zes the metal ion-dependent oxidation of (+)-tartrate to yield oxaloglycolate and NADH.

293 Simple dehydration of tartrates to oxaloacetate and an ensuing decarboxylation

294 ate kinase and that the serine cycle and the tartrate utilization pathway share a series of reactions

295 The commonly used sedative zolpidem tartrate was implicated in 11.5% (95% CI, 9.5%-13.4%) of

296 omplexed with the competitive inhibitor l(+)-tartrate was solved using single-wavelength anomalous di

297 eridinyl]ethyl]-2,4(1H,3H)-quinazolinedion e tartrate) was ineffective.

298 nding of the bis(alpha-hydroxycarbolxylate), tartrate, was assessed and compared to the corresponding

299 3 hydroxyl group on the D(-)-stereoisomer of tartrate, which does not significantly inhibit prostatic

300 is degraded via L-idonate to L-threarate (L-tartrate), with the latter arising from carbons 1-4 of a